Across TCGA pan-cancer cohorts, TAS2R60 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TAS2R60 data layer compared with 13 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TAS2R60 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TAS2R60 expression acts as an unfavorable survival marker.
BLCA, STAD, and ESCA are the cancer types where TAS2R60 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.